bmp Ventures announces Metabolon Inc.’s acquisition of Metabolomic Discoveries GmbH, an investment of the Frühphasenfonds Brandenburg fund

Berlin, 08 September 2017 – Metabolon Inc. has acquired all shares in Metabolomic Discoveries GmbH (“Metabolomic”), an investment of the Frühphasenfonds Brandenburg fund. This was announced today by bmp Ventures AG, which manages the fund launched by Investitionsbank des Landes Brandenburg (ILB) on behalf of the Brandenburg Ministry of Economics. The parties have agreed not to disclose the details of the transaction.

Metabolomic is an innovative service provider in the field of metabolite analysis. It is based in Potsdam and was founded in 2009. Metabolomic has developed a technology platform with which highly complex metabolite analyses of up to 1,000 metabolic products can be performed, interpreted and measured using a single sample. Metabolite analysis offers extensive insight into metabolic processes in humans. This was used for a product designed to perform complete blood analyses with just a drop of blood and that was launched onto the market for the first time in 2015.

The Frühphasenfonds Brandenburg fund has been investing in the company since 2010 and has financed and facilitated the development of this technology with its investment.

This acquisition will give us the opportunity to provide new services and precision medical products to a wide group of researchers and hospitals,” explained Dr. Nicolas Schauer, Managing Director and co-founder of Metabolomic Discoveries. He will also be joining Metabolon‘s Executive Team as Managing Director. “I am looking forward to speeding up the development of the metabolomics market in Europe with Metabolon.

Dr Jan Alberti, a member of the Executive Board and partner in charge at bmp Ventures AG, added: “As the first and only investor, we have helped the Metabolomic team build up the company over the last seven years. Metabolomic has become a successful and competitive biotechnology company with international customers. By selling our stake in Metabolon, one of the world’s leading metabolite and biomarker companies, Metabolomic will further expand as a European branch in Potsdam. We wish the team every success in the steps to come.

Ralf Hoffmann, a lawyer and tax consultant based in Berlin, provided legal assistance to the seller.
(www.hoffmann-law.de)

About BFB Frühphasenfonds Brandenburg GmbH:
BFB Frühphasenfonds Brandenburg GmbH (Frühphasenfonds Brandenburg) invests in young, innovative companies in the State of Brandenburg with the aim of strengthening the equity base of these companies in the early phase. The fund, which has a volume of EUR 25 million, was designed and set up by InvestitionsBank des Landes Brandenburg (ILB) on behalf of the Ministry for Economics and European Affairs of the State of Brandenburg. 75% of the fund’s resources are provided by the European Regional Development Fund (ERDF), 20% by budget funds of the State of Brandenburg and 5% by bmp Ventures AG. bmp (www.bmp.com) has been commissioned to manage the fund, which completed its investment phase at the end of 2014.

About bmp Ventures AG:
With a background of experience of more than 250 investments in almost all technology segments, the majority of which were early phase, bmp is one of the most experienced venture capital investors in Germany. In addition to direct investments, bmp's activities also include managing risk capital funds for KfW Bankengruppe and DEG - Deutsche Investitions- und Entwicklungsgesellschaft.
Besides the BFB Frühphasenfonds Brandenburg bmp currently manages the IBG funds in Saxony-Anhalt.

Contact

bmp Ventures AG
Corinna Riewe
- Public Relations -
phone: +49 30 2030 5567
criewe@bmp.com
www.bmp.com

Metabolomic Discoveries GmbH
Dr. Nicolas Schauer
phone: +49 179 7963651
pr@metabolomicdiscoveries.com
www.metabolomicdiscoveries.com